Prenatal was the largest of BillionToOne, Inc.’s 3 reported lines in fiscal 2025, at $277.11M — 91% of $305.11M.
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Prenatal | $68.80M | $145.90M | $277.11M |
| Oncology | — | $2.94M | $24.95M |
| Clinical Trial Support & Other Services | $2.93M | $3.74M | $3.05M |
| Total | $71.73M | $152.58M | $305.11M |
In fiscal 2025, which ended December 31, 2025, the 3 revenue lines BillionToOne, Inc. reported in this breakdown added up to $305.11M. That was up 100.0% from $152.58M in fiscal 2024. Prenatal was the largest revenue line, at $277.11M or 90.8% of the total, followed by Oncology ($24.95M, 8.2%) and Clinical Trial Support & Other Services ($3.05M, 1.0%). Together, the two largest revenue lines made up 99.0% of this total.
Compared with fiscal 2024, Oncology grew the fastest, rising 747.6% to $24.95M.
Oncology was first reported as a separate revenue line in fiscal 2024. This breakdown covers every fiscal year from 2023 to 2025, as reported in BillionToOne, Inc.'s annual filings.
BillionToOne, Inc. (BLLN) breaks its revenue down by revenue line. In fiscal 2025, its largest revenue line was Prenatal, with $277.11M or 90.8% of the total, followed by Oncology at $24.95M (8.2%).
Prenatal was BillionToOne, Inc.'s largest revenue line in fiscal 2025, with $277.11M in revenue, 90.8% of the $305.11M reported across its 3 revenue lines.
Of the BillionToOne, Inc. revenue lines reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Oncology grew the fastest, rising 747.6% from $2.94M to $24.95M.
Every figure is taken from BillionToOne, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2023 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.